好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

White Matter Free Water in Cerebral Amyloid Angiopathy: a Diffusion-Based Study
Cerebrovascular Disease and Interventional Neurology
P9 - Poster Session 9 (11:45 AM-12:45 PM)
13-012
  • We aimed to determine whether free water (FW) is elevated in cerebral amyloid angiopathy (CAA) compared to non-CAA participants and to assess FW's neuroimaging and cognitive associations in CAA compared to other conventional magnetic resonance imaging (MRI) markers of cerebral small vessel disease (cSVD).

  • CAA is currently diagnosed with a set of clinical-neuroimaging criteria, but effective biomarkers are still lacking for early CAA diagnosis. An MRI based biomarker, called FW, was developed to differentiate extracellular water from the intracellular tissue component. It is unknown whether FW carries information about CAA-related tissue damage independent of previously characterized MRI markers of cSVD.
  • Participants were recruited from a memory-clinic cohort, and were stratified into CAA and non-CAA groups. FW was computed using a freely available pipeline. Diffusion metrics were analyzed within the white matter skeleton, using tract-based spatial statics. We compared FW values between the groups. Within the CAA group, we explored FW's association with conventional MRI markers of cSVD and with cognitive scores in multiple domains.

  • Eighty-eight CAA [mean age 75.6(54.9-95.9) years; 47.7% female] and 38 non-CAA subjects [mean age 71.6(56.3-86.1) years; 44.7% female] were included in the analysis. FW values were higher (0.24±0.04; mean ± SD) in the CAA than in the non-CAA group (0.18±0.03; p <0.0001). Within the CAA group, in multivariable regression analyses adjusted for age, FW was associated with cerebral microbleeds (β=0.0003, p=0.006), white matter hyperintensities volume (β=12.57, p=<0.0001), cortical superficial siderosis (β=0.08, p=0.03), perivascular spaces in the centrum semiovale  (β=0.14, p=0.0002) and brain volume (β=-0.88, p=0.05). In simple linear regression model, FW was associated with executive function (EF) (β=-8.23, p=0.02) and Mini-Mental State Examination (MMSE) (β=-18.2, p=0.05).

  • Participants with CAA have higher FW values compared to non-CAA. In CAA participants, FW is significantly associated with conventional MRI markers of cSVD, with EF and with MMSE.

Authors/Disclosures
Suzete N. Farias Da Guarda, MD, PhD (Massachusetts General Hospital)
PRESENTER
Prof. Farias Da Guarda has nothing to disclose.
Maria Clara Zanon Zotin, MD, PhD Dr. Zanon Zotin has nothing to disclose.
Hilde d. van den Brink, PhD Ms. van den Brink has nothing to disclose.
Dorothee Schoemaker, PhD Dr. Schoemaker has received personal compensation for serving as an employee of WCG.
Anthipa Chokesuwattanaskul, MD Dr. Chokesuwattanaskul has nothing to disclose.
Steven M. Greenberg, MD, PhD, FAAN Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. The institution of Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care.
Anand Viswanathan, MD (Massachusetts General Hospital) Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam Pharmaceuticals. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharmaceuticals.